Correction to: Nature Medicine https://doi.org/10.1038/s41591-022-01962-5. Published online 12 September 2022.
In the version of this article initially published, the first sentence of the Fig. 4a caption (now reading “The expression of different NK cell surface receptors was determined by scRNA-seq”) was incorrectly preceded by the text “Association between gene expression in NK cells and the percentage of viable tumor cells,” which has now been removed from the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chaft, J.E., Oezkan, F., Kris, M.G. et al. Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med 30, 303 (2024). https://doi.org/10.1038/s41591-023-02627-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02627-7
